On Friday, Shares of CyberArk Software, Ltd. (NASDAQ:CYBR), gained 7.58% to $66.13.
CyberArk Software, declared financial results for the first quarter ended March 31, 2015.
Financial Highlights for the First Quarter Ended March 31, 2015
- Total revenue was $32.9 million, up 89% year-over-year contrast with the first quarter of 2014.
- License revenue was $20.0 million, up 119% contrast with the first quarter of 2014.
- Maintenance and Professional Services revenue was $12.9 million, up 56% year-over-year.
CyberArk Software Ltd. develops, markets, and sells software-based IT security solutions that protect organizations from cyber attacks in the United States and internationally. The company offers privileged account security solution to secure, manage, and monitor privileged account access and activities.
Shares of The Goodyear Tire & Rubber Company (NASDAQ:GT), inclined 2.22% to $29.43, during its last trading session, hitting its highest level.
The Goodyear Tire & Rubber Company, has begun using a next-generation silica to enhance the fuel-efficiency of its tires. This new silica will be first used in the Goodyear EfficientGrip SUV tire, which is being launched this month in Latin American markets. Tires containing the silica also will be introduced in other regions within the next year.
For more than a decade, Goodyear researchers worked with PPG Industries to examine the effects of chemically treated silica on tire performance. The aim was to further improve rolling resistance without having a detrimental effect on traction in wet conditions. In Goodyear’s new EfficientGrip SUV tire, this next generation silica was used in a new tread compound and a new tread pattern to provide both improved rolling resistance and improved wet traction.
The Goodyear Tire & Rubber Company develops, manufactures, distributes, and sells tires, and related products and services in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers various lines of rubber tires for automobiles, trucks, buses, aircraft, motorcycles, farm implements, earthmoving and mining equipment, industrial equipment, and various other applications under the Goodyear, Dunlop, Kelly, Debica, Sava, Fulda, and various other Goodyear owned house brands, in addition to under the private-label brands.
At the end of Friday’s trade, Shares of Scientific Games Corporation (NASDAQ:SGMS), lost -9.26% to $12.35.
Scientific Games Corporation, stated financial results for the first quarter ended March 31, 2015.
Gaming Segment Financial Highlights
- Revenue raised $262.4 million, inclusive of a $1.9 million unfavorable foreign currency translation impact, principally due to $286.7 million from Bally, which comprised of $142.6 million in service revenue and $144.1 million in product sales revenue, partially offset by $24.3 million lower revenue in legacy Gaming (i.e. that which existed preceding to the Bally acquisition).
- Gaming operations revenue raised $100.3 million year-over-year reflecting $101.3 million from Bally and growth in the overall average daily revenue per unit from the legacy Gaming business, partially offset by a decrease in the legacy Gaming average installed base.
- The inclusion of 15,073 Bally WAP, premium and daily-fee units to the ending installed base was partially offset by a 667 unit decrease in the legacy Gaming installed base. The total period-end installed base reduced 477 units on a quarterly sequential basis. The inclusion of Bally’s installed base of WAP, premium and daily-fee units led to a $23.53 per unit decrease in average daily revenue, while average daily revenue for the legacy Gaming installed base raised 9%, or $6.54, year-over-year, principally reflecting the strong growth in the performance of WMS WAP games.
- The year-over-year enhance in the quarter-end installed base of other leased and participation units reflected the inclusion of 17,752 Bally units and a 96 unit enhance in the legacy Gaming installed base. The addition of Bally’s other leased and participation units led to a $3.99 enhance in daily average revenue per unit with the balance of the enhance due to improved performance in the legacy Gaming installed base, particularly games installed in our UK customers’ betting shops.
Scientific Games Corporation develops technology-based products and services, and associated content for the gaming and lottery industries worldwide. The company operates through three segments: Gaming, Lottery, and Interactive.
Finally, Calithera Biosciences, Inc. (NASDAQ:CALA), ended its last trade with 45.69% surge, and closed at $13.87.
Calithera Biosciences, declared its financial results for the first quarter ended March 31, 2015. As of March 31, 2015, cash, cash equivalents and investments totaled $94.3 million.
First Quarter 2015 and Recent Highlights
- Enrollment continues across CB-839 Phase Ib expansion cohorts. Updated data from the Phase I solid tumor trial has been accepted for presentation at the 2015 American Society of Clinical Oncology (ASCO) annual meeting on Saturday, May 30, 2015.
- Hexokinase II inhibitors research license. In March 2015, Calithera gained exclusive worldwide rights to TransTech Pharma’s portfolio of hexokinase II inhibitors. Hexokinase II is the first and rate-limiting enzyme in the pathway that enables cancer cells to convert glucose to energy and building blocks that feed cancer growth. It is the third program in Calithera’s pipeline.
- Preclinical findings, counting biomarker data, presented at the American Association of Cancer Research. In April 2015, Calithera presented preclinical data that could ultimately direct the development of CB-839 in non-small cell lung cancer, renal cell carcinoma, and other solid tumor and hematologic indications. The presentations added KRAS and EGFR to our expanding list of potential biomarkers and reiterated data on preclinical single agent activity. Additionally, preclinical synergy studies with signal transduction inhibitors and other anti-cancer agents were also presented.
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
